A recent clinical trial has demonstrated that a single infusion of a stem cell-based therapy, known as zimislecel (VX-880) developed by Vertex Pharmaceuticals, may effectively cure severe type 1 diabetes in patients. In the Phase I/II trial, 10 out of 12 participants no longer required insulin injections one year after treatment, while the remaining two patients needed substantially lower doses. The therapy involves the infusion of lab-grown pancreatic islet cells derived from stem cells, which restored insulin production in the patients. The treatment also resulted in a significant reduction in HbA1c levels from approximately 10% to below the diabetic threshold, with no severe hypoglycemic events reported after 90 days. Despite the promising results, the therapy requires lifelong immune suppression to prevent rejection. The trial, which has been described as a landmark study, offers hope for long-term insulin independence and a potential functional cure for people with the most severe form of type 1 diabetes. The University of Toronto and other research institutions have contributed to this breakthrough, which is expected to lead to broader clinical applications and global rollout in the near future.